CN104918598B - Bpo清洗凝胶组合物 - Google Patents
Bpo清洗凝胶组合物 Download PDFInfo
- Publication number
- CN104918598B CN104918598B CN201380070271.8A CN201380070271A CN104918598B CN 104918598 B CN104918598 B CN 104918598B CN 201380070271 A CN201380070271 A CN 201380070271A CN 104918598 B CN104918598 B CN 104918598B
- Authority
- CN
- China
- Prior art keywords
- composition
- bpo
- acne
- weight
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 claims abstract description 135
- 239000004342 Benzoyl peroxide Substances 0.000 claims abstract description 126
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims abstract description 126
- 235000019400 benzoyl peroxide Nutrition 0.000 claims abstract description 126
- 206010000496 acne Diseases 0.000 claims abstract description 55
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 48
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims abstract description 21
- 238000004140 cleaning Methods 0.000 claims abstract description 19
- 235000011478 zinc gluconate Nutrition 0.000 claims abstract description 18
- 229960000306 zinc gluconate Drugs 0.000 claims abstract description 18
- 239000011670 zinc gluconate Substances 0.000 claims abstract description 18
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims abstract description 17
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims abstract description 17
- 239000003349 gelling agent Substances 0.000 claims abstract description 17
- 239000003945 anionic surfactant Substances 0.000 claims abstract description 13
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 12
- 239000006260 foam Substances 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 150000001450 anions Chemical class 0.000 claims abstract description 7
- 208000017520 skin disease Diseases 0.000 claims abstract description 6
- -1 acyl isethionic acid Sodium Chemical compound 0.000 claims description 40
- 229920001983 poloxamer Polymers 0.000 claims description 27
- 238000002360 preparation method Methods 0.000 claims description 22
- 150000002148 esters Chemical class 0.000 claims description 19
- 125000002252 acyl group Chemical group 0.000 claims description 17
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 14
- 229940009868 aluminum magnesium silicate Drugs 0.000 claims description 14
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 claims description 14
- 239000000080 wetting agent Substances 0.000 claims description 13
- 239000011701 zinc Substances 0.000 claims description 13
- 229910052725 zinc Inorganic materials 0.000 claims description 13
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 12
- 229920001285 xanthan gum Polymers 0.000 claims description 11
- 239000000230 xanthan gum Substances 0.000 claims description 11
- 235000010493 xanthan gum Nutrition 0.000 claims description 11
- 229940082509 xanthan gum Drugs 0.000 claims description 11
- JDRSMPFHFNXQRB-IBEHDNSVSA-N decyl glucoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JDRSMPFHFNXQRB-IBEHDNSVSA-N 0.000 claims description 10
- 229920002125 Sokalan® Polymers 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical class OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 6
- 239000000440 bentonite Substances 0.000 claims description 6
- 229910000278 bentonite Inorganic materials 0.000 claims description 6
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 6
- 150000004676 glycans Chemical class 0.000 claims description 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 6
- 229920001282 polysaccharide Chemical class 0.000 claims description 6
- 239000005017 polysaccharide Chemical class 0.000 claims description 6
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 5
- 239000011149 active material Substances 0.000 claims description 5
- 229960001631 carbomer Drugs 0.000 claims description 5
- 229920002678 cellulose Chemical class 0.000 claims description 5
- 239000001913 cellulose Chemical class 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 229960000502 poloxamer Drugs 0.000 claims description 5
- 150000003460 sulfonic acids Chemical class 0.000 claims description 5
- 239000000470 constituent Substances 0.000 claims description 4
- 239000003792 electrolyte Substances 0.000 claims description 4
- 238000006386 neutralization reaction Methods 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 abstract description 25
- 230000000699 topical effect Effects 0.000 abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 49
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 41
- 239000000126 substance Substances 0.000 description 37
- 239000008213 purified water Substances 0.000 description 30
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- 210000003491 skin Anatomy 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 15
- 239000003921 oil Substances 0.000 description 15
- 239000011734 sodium Substances 0.000 description 15
- 229910052708 sodium Inorganic materials 0.000 description 15
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 14
- 230000006641 stabilisation Effects 0.000 description 14
- 238000011105 stabilization Methods 0.000 description 14
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 10
- 238000002156 mixing Methods 0.000 description 9
- 229920006037 cross link polymer Polymers 0.000 description 8
- 229960004949 glycyrrhizic acid Drugs 0.000 description 8
- 235000019410 glycyrrhizin Nutrition 0.000 description 8
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 8
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 8
- 229920001577 copolymer Polymers 0.000 description 7
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 7
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 238000005070 sampling Methods 0.000 description 7
- XEFAJZOBODPHBG-UHFFFAOYSA-N 1-phenoxyethanol Chemical compound CC(O)OC1=CC=CC=C1 XEFAJZOBODPHBG-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000001685 glycyrrhizic acid Substances 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 229960003080 taurine Drugs 0.000 description 6
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 5
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 150000001336 alkenes Chemical class 0.000 description 5
- 239000002280 amphoteric surfactant Substances 0.000 description 5
- 229960003720 enoxolone Drugs 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 238000005187 foaming Methods 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 229920000570 polyether Polymers 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 3
- 206010033733 Papule Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 235000011399 aloe vera Nutrition 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- GLSRFBDXBWZNLH-UHFFFAOYSA-L disodium;2-chloroacetate;2-(4,5-dihydroimidazol-1-yl)ethanol;hydroxide Chemical compound [OH-].[Na+].[Na+].[O-]C(=O)CCl.OCCN1CCN=C1 GLSRFBDXBWZNLH-UHFFFAOYSA-L 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 150000008131 glucosides Chemical class 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- 229920000058 polyacrylate Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 230000037307 sensitive skin Effects 0.000 description 3
- 229940096501 sodium cocoamphoacetate Drugs 0.000 description 3
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 150000003871 sulfonates Chemical class 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 2
- CYUZOYPRAQASLN-UHFFFAOYSA-N 3-prop-2-enoyloxypropanoic acid Chemical compound OC(=O)CCOC(=O)C=C CYUZOYPRAQASLN-UHFFFAOYSA-N 0.000 description 2
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 2
- 239000013531 ACULYN rheology modifier Substances 0.000 description 2
- 208000003911 Acne Keloid Diseases 0.000 description 2
- 206010000501 Acne conglobata Diseases 0.000 description 2
- 206010000507 Acne infantile Diseases 0.000 description 2
- 208000020154 Acnes Diseases 0.000 description 2
- 241001116389 Aloe Species 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000228245 Aspergillus niger Species 0.000 description 2
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010051651 Dermatitis papillaris capillitii Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000589236 Gluconobacter Species 0.000 description 2
- 241000202807 Glycyrrhiza Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- 241000871495 Heeria argentea Species 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 2
- 244000147568 Laurus nobilis Species 0.000 description 2
- 235000017858 Laurus nobilis Nutrition 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 241000228143 Penicillium Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004721 Polyphenylene oxide Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 210000001193 acne keloid Anatomy 0.000 description 2
- 229960002916 adapalene Drugs 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229960003168 bronopol Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000005202 decontamination Methods 0.000 description 2
- 230000003588 decontaminative effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 2
- 229940043276 diisopropanolamine Drugs 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 229940049906 glutamate Drugs 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 229940074047 glyceryl cocoate Drugs 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 229960005280 isotretinoin Drugs 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- NEMFQSKAPLGFIP-UHFFFAOYSA-N magnesiosodium Chemical compound [Na].[Mg] NEMFQSKAPLGFIP-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 150000005209 naphthoic acids Chemical class 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 201000004700 rosacea Diseases 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 229940057950 sodium laureth sulfate Drugs 0.000 description 2
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LPLVUJXQOOQHMX-MOGLOQIBSA-N (2s,3s,4s,5r,6r)-6-[(2r,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-c Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-MOGLOQIBSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- QHZLMUACJMDIAE-SFHVURJKSA-N 1-hexadecanoyl-sn-glycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)CO QHZLMUACJMDIAE-SFHVURJKSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 1
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- RWLALWYNXFYRGW-UHFFFAOYSA-N 2-Ethyl-1,3-hexanediol Chemical compound CCCC(O)C(CC)CO RWLALWYNXFYRGW-UHFFFAOYSA-N 0.000 description 1
- QTDIEDOANJISNP-UHFFFAOYSA-N 2-dodecoxyethyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOCCOS(O)(=O)=O QTDIEDOANJISNP-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- RFRMMZAKBNXNHE-UHFFFAOYSA-N 6-[4,6-dihydroxy-5-(2-hydroxyethoxy)-2-(hydroxymethyl)oxan-3-yl]oxy-2-(hydroxymethyl)-5-(2-hydroxypropoxy)oxane-3,4-diol Chemical compound CC(O)COC1C(O)C(O)C(CO)OC1OC1C(O)C(OCCO)C(O)OC1CO RFRMMZAKBNXNHE-UHFFFAOYSA-N 0.000 description 1
- 241000589220 Acetobacter Species 0.000 description 1
- 206010000503 Acne cystic Diseases 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- YFKTWWJKGDLJDH-UHFFFAOYSA-N CC(O)CO.CCCCCCCCC(O)=O Chemical class CC(O)CO.CCCCCCCCC(O)=O YFKTWWJKGDLJDH-UHFFFAOYSA-N 0.000 description 1
- ONAIRGOTKJCYEY-XXDXYRHBSA-N CCCCCCCCCCCCCCCCCC(O)=O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ONAIRGOTKJCYEY-XXDXYRHBSA-N 0.000 description 1
- 240000004385 Centaurea cyanus Species 0.000 description 1
- 235000005940 Centaurea cyanus Nutrition 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229910001051 Magnalium Inorganic materials 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 101100412856 Mus musculus Rhod gene Proteins 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- QHZLMUACJMDIAE-UHFFFAOYSA-N Palmitic acid monoglyceride Natural products CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 1
- 241000282372 Panthera onca Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000004115 Sodium Silicate Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- ZPVGIKNDGJGLCO-VGAMQAOUSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZPVGIKNDGJGLCO-VGAMQAOUSA-N 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001294 alanine derivatives Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- FSLPMRQHCOLESF-UHFFFAOYSA-N alpha-amyrenol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C FSLPMRQHCOLESF-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940036589 antiprotozoals Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 description 1
- WNJCXXCSCHKPRY-UHFFFAOYSA-N azanium 2-(dimethylamino)ethanesulfonate Chemical compound [NH4+].CN(C)CCS([O-])(=O)=O WNJCXXCSCHKPRY-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229940106010 beheneth-25 Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- JFSHUTJDVKUMTJ-QHPUVITPSA-N beta-amyrin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C JFSHUTJDVKUMTJ-QHPUVITPSA-N 0.000 description 1
- QQFMRPIKDLHLKB-UHFFFAOYSA-N beta-amyrin Natural products CC1C2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C)CCC1(C)C QQFMRPIKDLHLKB-UHFFFAOYSA-N 0.000 description 1
- PDNLMONKODEGSE-UHFFFAOYSA-N beta-amyrin acetate Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC23C)C1(C)C PDNLMONKODEGSE-UHFFFAOYSA-N 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 239000002734 clay mineral Substances 0.000 description 1
- 229940080421 coco glucoside Drugs 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- KQWGXHWJMSMDJJ-UHFFFAOYSA-N cyclohexyl isocyanate Chemical compound O=C=NC1CCCCC1 KQWGXHWJMSMDJJ-UHFFFAOYSA-N 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical group O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 229960001083 diazolidinylurea Drugs 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- POCFBDFTJMJWLG-UHFFFAOYSA-N dihydrosinapic acid methyl ester Natural products COC(=O)CCC1=CC(OC)=C(O)C(OC)=C1 POCFBDFTJMJWLG-UHFFFAOYSA-N 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- JRHWWJSWHFFZRY-XRIOVQLTSA-L disodium;(2s)-2-(octanoylamino)pentanedioate Chemical compound [Na+].[Na+].CCCCCCCC(=O)N[C@H](C([O-])=O)CCC([O-])=O JRHWWJSWHFFZRY-XRIOVQLTSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- MPVXINJRXRIDDB-VCDGYCQFSA-N dodecanoic acid;(2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCCCCCC(O)=O MPVXINJRXRIDDB-VCDGYCQFSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229960005082 etohexadiol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000002342 glycyrrhetinic acids Chemical class 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920003111 hydroxyethyl cellulose HHX Polymers 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000005005 intertrigo Diseases 0.000 description 1
- 150000008040 ionic compounds Chemical class 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 1
- 229940094522 laponite Drugs 0.000 description 1
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 description 1
- 229940048848 lauryl glucoside Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-N noncarboxylic acid Natural products CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940086539 peg-7 glyceryl cocoate Drugs 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- FBCQUCJYYPMKRO-UHFFFAOYSA-N prop-2-enyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC=C FBCQUCJYYPMKRO-UHFFFAOYSA-N 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- ATCCIZURPPEVIZ-SCSAIBSYSA-N roche ester Chemical compound COC(=O)[C@H](C)CO ATCCIZURPPEVIZ-SCSAIBSYSA-N 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 229940045944 sodium lauroyl glutamate Drugs 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000019795 sodium metasilicate Nutrition 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 229910052911 sodium silicate Inorganic materials 0.000 description 1
- IWIUXJGIDSGWDN-UQKRIMTDSA-M sodium;(2s)-2-(dodecanoylamino)pentanedioate;hydron Chemical compound [Na+].CCCCCCCCCCCC(=O)N[C@H](C([O-])=O)CCC(O)=O IWIUXJGIDSGWDN-UQKRIMTDSA-M 0.000 description 1
- ZUFONQSOSYEWCN-UHFFFAOYSA-M sodium;2-(methylamino)acetate Chemical compound [Na+].CNCC([O-])=O ZUFONQSOSYEWCN-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229940100459 steareth-20 Drugs 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229940037562 ziana Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/38—Percompounds, e.g. peracids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/463—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/604—Alkylpolyglycosides; Derivatives thereof, e.g. esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/90—Block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及包含BPO的局部皮肤病学用/药物组合物，其中所述组合物是具有合意的耐受性、稳定性和发泡性能的清洗组合物。所述组合物包含：a)过氧化苯甲酰(BPO)，b)至少一种温和的表面活性剂，其选自阴离子和/或非离子表面活性剂类别，c)葡糖酸锌，d)甘草酸二钾，e)至少一种胶凝剂。该组合物优选呈水性凝胶或含水醇性凝胶的形式。本发明还涉及此类组合物用于治疗皮肤病症(尤其是在痤疮的治疗中)的用途。
Description
技术领域
本发明涉及用于局部施用的组合物，及涉及其作为化妆产品或药物产品的用途，所述组合物用于皮肤病症的治疗，尤其用于痤疮的治疗。
背景技术
痤疮是一种常见的多因素病理(multi-factor pathology)，其侵袭富含皮脂腺的皮肤(面部、肩部区域、手臂和擦烂区域(intertriginal areas))。这是最常见的皮肤病发生形式。以下五种致病因素在痤疮的形成中发挥了决定性的作用：
1.遗传素因；
2.皮脂过度产生(皮脂溢)；
3.雄激素；
4.毛囊角化病症(粉刺产生(comedogenesis))，和
5.细菌定殖和炎性因素。
存在着数种形式的痤疮，所有形式的共同因素是侵袭毛囊皮脂腺滤泡。可特别提到聚合性痤疮、颈项部瘢痕瘤性痤疮、药物性痤疮(acne medicamentosa)、复发性粟粒状痤疮、坏死性痤疮、新生儿痤疮、经前痤疮、职业性痤疮、玫瑰痤疮、老年性痤疮、日光性痤疮和寻常痤疮。
寻常痤疮(也称为多形态的青少年痤疮)是最常见的。其包含四个阶段：
-阶段1对应于粉刺性痤疮(comedonic acne)，特征在于大量开放的和/或闭合的粉刺和大量微囊；
-阶段2，或丘疹脓疱性痤疮(papulopustular acne)，具有轻度至中度的严重性。其特征在于存在开放的和/或闭合的粉刺，存在微囊，而且还存在红色丘疹和脓疱。其主要影响面部并留下少许疤痕；
-阶段3，或丘疹粉刺性痤疮(papulocomedonic acne)，更加严重并扩展至背部、胸部和肩部。其伴随大量疤痕；
-阶段4，或结节囊性痤疮(nodulocystic acne)，伴随众多疤痕。其展现出结节及还有疼痛的大体积的(voluminous)深红色脓疱。
可用诸如抗皮脂溢药剂和抗感染药之类的活性药剂(例如过氧化苯甲酰(特别由Pierre Fabre公司销售的产品))、用维甲类(例如维甲酸(特别由Galderma销售的产品)或异维甲酸(由Roche Laboratoires销售的产品))、或用萘甲酸衍生物来治疗上述各种形式的痤疮。萘甲酸衍生物(例如6-[3-(1-金刚烷基)-4-甲氧基苯基]-2-萘甲酸，通常将其称为阿达帕林(由Galderma销售的产品))被广泛描述并公认为是与维甲酸同样有效的用于痤疮治疗的活性成分(Ioannides D.,Rigopoulos D.和Katsambas A.,2002.Topical adapalene gel 0.1％vs.isotretinoingel0.05％in the treatment of acne vulgaris:a randomized open-label clinicaltrial[Br J Dermatol.Sep；147(3):523-7]。
使用Rx(有处方)产品(主要是局部/口服的维甲类)出现的一些不良事件(AE)产生重要的相关AE和频繁的皮肤副作用，例如Ziana：27％对象(subject)具有相关施用位点AE，且最重要的是皮肤干燥。
皮肤科医生推荐的用于痤疮治疗的皮肤护理方案包括以下步骤：
-步骤1：清洗
-步骤2：用药治疗(Rx治疗)
-步骤3：水合和保护
拥有改善痤疮征兆/症状的护肤产品是有用的。
已经充分确定Rx治疗是有效的。但是对新的良好耐受的局部药物组合物存在需求，所述组合物兼具治疗、改善皮肤质量和清洗皮肤(优选痤疮患者的皮肤)的性能。从而步骤2的用药治疗根据本发明是任选的或可被认为通过在组合物中使用过氧化苯甲酰(BPO)来自动实现。
发明内容
本发明提供局部皮肤病学用(dermatological)/药物组合物并特别提供稳定和良好耐受的BPO清洗组合物(wash composition)。
使BPO与皮肤接触时，其效力与其分解相关联。在该分解期间产生的自由基的氧化性能产生了期望的效果。因此，为了维持过氧化苯甲酰的最佳效力，防止其在使用前(即，储存期间)的分解是重要的。
BPO是一种不稳定的并与一大批原材料(特别是表面活性剂和油)反应的化合物。这种固有的不稳定性使得BPO难以在最终产品(特别是含有表面活性剂(出于它们的清洁和发泡性能的益处)的清洗组合物)中配制。
发明人还已观察到，众所周知的表面活性剂(例如两性表面活性剂)与BPO不相容且导致较不稳定的组合物。还已知具有清洁性能的传统的表面活性剂对皮肤有刺激作用。
BPO清洗产品已存在于市场上；但是，很多不是很稳定。数种产品使用两性表面活性剂，其已经显示使BPO不稳定。从而存在着这些组合物可能较不化学稳定的风险。这些产品中的一些在包装上表明在使用之前需要有力摇晃该产品。这表明组合物和/或BPO悬浮液经历沉淀并因此展现物理不稳定的形式。另外，这些产品中的一些使用的BPO和/或一些表面活性剂的浓度如此之高以致加剧了与痤疮治疗相关的刺激。一些患者的意见突出了各种产品的刺激作用。这些产品中的数种不具有患者所优选的最佳发泡性能。这些限制影响患者顺从性并最终影响痤疮治疗的效力。
从而，仍然对非刺激性的BPO发泡清洗产品存在需求。在具体实施方案中，本发明提供BPO清洗组合物，优选为清洗凝胶形式，具有期望的耐受性、稳定性和发泡性能。
本专利权人已发现，该需要可在相同组合物中使用至少一种具体的表面活性剂、葡糖酸锌和甘草酸或甘草次酸的盐或衍生物得到满足。
具体实施方式
因此本发明的一个方面是组合物，其为局部清洗组合物，包含：
a.过氧化苯甲酰(BPO)
b.至少一种与BPO相容的温和的表面活性剂，其选自阴离子和/或非离子表面活性剂类别
c.葡糖酸锌
d.d)甘草酸或甘草次酸的盐或衍生物
所述组合物包括过氧化苯甲酰(BPO)。
可将BPO溶解或分散在组合物中。在本发明的具体实施方案中，过氧化苯甲酰在组合物中呈分散形式。通过根据本发明的分散形式，BPO被认为在组合物中维持在稳定的悬浮液中。或者，过氧化苯甲酰被封装(如US专利7,758,888中所述的封装技术除外)或被吸附或吸收/涂布到支撑物上或作为自由形式使用。
例如，可将BPO封装在由多孔微球构成的聚合物系统中，例如由Cardinal Health以过氧化苯甲酰MICROSPONGE P009A的名称销售的微海绵或甲基丙烯酸烯丙酯交联聚合物例如由Amcol HBS以名称Poly-Pore 438BP/过氧化苯甲酰销售的多孔材料(Poly-pore)。
优选地，组合物包含介于0.5％和10％w/w之间的BPO，优选介于1％w/w和5％w/w之间及优选介于2.5％w/w和3.5％w/w之间。重量对重量百分比(％w/w)由相对于组合物的总重量的活性成分的重量表示。
本专利权人已注意到，使用含有相对低浓度的BPO(例如<5％w/w BPO)的制剂比使用较高浓度的(制剂)更难以实现BPO的化学稳定性。但是，由于低刺激性和高耐受性的需求，本发明的组合物应当含有优选不高于3.5％的浓度的BPO。该低浓度导致确保随着时间推移在组合物中可接受的BPO稳定性的额外难度。
本发明人已观察到，大多数众所周知的表面活性剂与BPO不相容且这导致较不稳定的组合物。还发现，在利用特定种类的表面活性剂时大大改善了包含BPO的组合物的化学稳定性。的确，考虑到一大批(large panel of)的表面活性剂，例如两性表面活性剂、非离子阴离子表面活性剂或阳离子表面活性剂，在实施例中已显示只有某些阴离子表面活性剂和非离子表面活性剂能够提供用于本发明目的的具有BPO的稳定的组合物。因此，在一种实施方案中，本发明提供组合物，该组合物具有新一代的非常温和的表面活性剂阴离子和/或非离子表面活性剂，其具有清洁和/或发泡性能，适用于痤疮和敏感皮肤且与BPO相容。
当其施用导致皮肤的最小程度的肿胀、紧绷和刺激时，则认为表面活性剂是温和的。月桂基硫酸钠经常被选作刺激性的表面活性剂的参考实例。温和的表面活性剂不仅比月桂基硫酸钠(SLS)的刺激性小，而且比月桂基醚硫酸钠(sodium lauryl ethersulphate)的刺激性小。通常，月桂基醚硫酸钠被认为是比SLS刺激性小的阴离子表面活性剂。
第一类表面活性剂是温和的表面活性剂，其具有去污，清洁和/或发泡性能，其选自阴离子表面活性剂和/或非离子表面活性剂，更具体地选自以下列表。它们可单独使用或组合使用。
阴离子表面活性剂之所以被如此命名归因于存在着分子的带负电荷的部分。阴离子表面活性剂的通式是RX-M+，其中R是碳链，M是中和基团(例如钠、钾、镁、锌、铵、三乙醇胺等)，X是带负电荷的物质(species)，其可以是以下任意种：羧酸根、磺酸根、硫酸根或磷酸根。这些表面活性剂拥有合意的发泡、去污和/或清洁性能。温和的阴离子表面活性剂更具体选自以下列表，单独使用或组合使用：
-羧酸盐衍生物
烷基羟乙磺酸盐或酰基羟乙磺酸盐(钠、钾、铵或镁盐)，如由Clariant以商品名Hostapon SCI-85G销售的椰油酰羟乙磺酸钠或来自Innospec的称为Iselux的月桂酰甲基羟乙磺酸钠；氨基酸和酰基氨基酸，例如谷氨酸盐、酰基谷氨酸盐：由Zschimmer&Schartz销售的称为Protelan AGL 95的月桂酰谷氨酸钠、也由Zschimmer&Schartz销售的并称为Protelan AG8的辛酰谷氨酸钠；肌氨酸盐或酰基肌氨酸盐，例如由Zschimmer&Schartz销售的称为Protelan LS9011的月桂酰肌氨酸钠；甘氨酸盐或酰基甘氨酸盐，例如来自Clariant的椰油酰甘氨酸盐Hostapon SG；脂肪酸精氨酸盐、丙氨酸盐(alaminate)或酰基丙氨酸盐(acyl alaminate)；酰基肽；椰油酰基苹果氨基酸，例如来自SEPPIC的Proteol APL；乳酰乳酸盐(lactylates)或酰基乳酰乳酸盐(acyl lactylates)；月桂基葡萄糖羧酸钠(来自Cognis的plantapon LGC Sorb)、月桂醇聚醚-13羧酸钠。
-硫酸盐衍生物：
烷基硫酸盐、烷基酰胺醚硫酸盐(alkylamido ether sulfates)、烷基芳基聚醚硫酸盐、单甘油酯硫酸盐；烷基醚硫酸盐，例如由Zschimmer&Schartz用商品名Zetesol ZN销售的椰油醇聚醚硫酸酯锌(Zinc coceth sulfate)
-磺酸盐衍生物：
烷基磺酸盐、烷基酰胺磺酸盐(alkylamidesulfonates)、烷基芳基、α-烯烃磺酸盐并优选C14-C16α-烯烃磺酸盐，优选其钠盐，例如来自Clariant的Hostapur OSB、HostapurOS Liq或来自Hunstman的Nansa LSS 495H或来自Stephan的BiotergeAS-90珠；链烷烃磺酸盐、烷基磺基琥珀酸盐，例如磺基琥珀酸二辛酯钠；烷基醚磺基琥珀酸盐(alkyl ethersulfosuccinates)、烷基酰胺磺基琥珀酸盐(alkylamidesulfosuccinates)、烷基磺基乙酸盐；烷基牛磺酸盐或酰基牛磺酸盐，例如脂肪酸甲基牛磺酸盐、由Seppic用商品名SomeponT25销售的甲基椰油酰牛磺酸钠
-磷酸盐衍生物：
烷基醚磷酸盐、烷基磷酸盐
非离子发泡表面活性剂的实例包括以下：
-烷基聚葡糖苷，例如椰油基葡糖苷(cocoglucoside)(来自Cognis的Plantacare818)、癸基葡糖苷(来自Cognis的Plantacare2000)，月桂基葡糖苷(来自Cognis的Plantacare 1200)、辛酰基/辛基葡糖苷(来自Seppic的Oramix CG110)
-烷氧基化醇，例如PEG-40甘油椰油酸酯(PEG-40 glyceryl cocoate)、甘油酯、失水山梨醇的酯和醚例如PEG-80失水山梨醇月桂酸酯(来自Cognis的Tween 28)
-糖酯，例如蔗糖月桂酸酯或蔗糖硬脂酸酯或蔗糖棕榈酸酯。
在优选的实施方案中，本发明提供组合物，所述组合物具有新一代的非常温和的表面活性剂，其适用于痤疮和敏感皮肤，并选自单独使用或组合使用的以下物质：椰油醇聚醚硫酸酯锌、椰油酰羟乙磺酸钠、月桂酰甲基羟乙磺酸钠、甲基椰油酰牛磺酸钠、C14-C16α-烯烃磺酸盐(优选其钠盐)及烷基聚葡糖苷例如癸基葡糖苷。
相应地，按相对于组合物的总重量的活性材料的重量(％w/w AM)表示，阴离子表面活性剂和/或非离子表面活性剂具有的总浓度介于0.2％w/w和20％w/w之间，优选介于0.25％w/w和10％w/w之间，甚至更优选介于0.5％w/w和5％w/w之间。
活性材料是指包括在制剂中的纯表面活性剂的百分比。在许多情况下，市售表面活性剂作为水溶液销售。AM的量可根据用来稀释纯的表面活性剂的水量和来自商业卖方供给的原材料等级而变化。
在根据本发明的组合物中，本领域技术人员将因此将调节(adapt)商品表面活性剂的正确浓度，以用在组合物中以达到所需浓度，优选相对于组合物的总重量计，介于0.5％和5％之间的活性材料。
根据本发明，组合物还包含葡糖酸锌。葡糖酸锌(也称zincum gluconium)是葡糖酸的锌盐。它是由2mol葡糖酸根对1mol锌构成的离子化合物。葡糖酸锌是作为膳食补充剂用于递送锌的广受欢迎的形式。
葡糖酸是天然存在的，且通过葡糖的发酵经工业化制备，典型地通过黑曲霉(Aspergillus niger)，也通过其它真菌，例如青霉属(Penicillium)，或通过细菌，例如醋酸杆菌属(Acetobacter)、假单胞菌属(Pseudomonas)和葡糖杆菌(Gluconobacter)进行。在其纯的形式中，它是白色至灰白色粉末。其也可通过电解氧化来制备，尽管这是一种较昂贵的方法。优点是较低的微生物学分布(profile)，和较完全的反应，得到具有较长货架期的产品。
在优选的实施方案中，按相对于组合物的总重量的重量表示，葡糖酸锌的浓度介于0.1和1％之间，优选介于0.15和0.3之间，更优选0.2％。
根据本发明，组合物还含有甘草酸或甘草次酸的盐或衍生物。
甘草酸来源于植物光果甘草(Glycyrrhiza glabra)或甘草根，其被认为提供抗刺激和抗炎症性能。甘草提取物的舒缓和镇定性能使得它们成为包括在用于敏感皮肤病症(例如湿疹、红斑(erhythema)、脂溢性皮炎(seborric dermatitis)和瘙痒)的治疗中的令人感兴趣的候选物。
甘草次酸是从甘草酸(别名：甘草甜素或甘草酸(glycyrrhizinic acid))的水解获得的β-香树素类型的五环三萜化合物衍生物，所述甘草酸从草药甘草获得。其用于调味且其掩蔽药物(如芦荟和奎宁)的苦味。其在消化性溃疡的治疗中是有效的，且还具有化痰(镇咳)性能。其具有一些额外的药理学性能，包括抗病毒、抗真菌、抗原生动物和抗细菌活性。
甘草次酸的化学结构
作为甘草酸盐和衍生物，可引用钾盐、钠盐、单铵盐可被引用作为实例。作为甘草酸盐和衍生物，可引用以下作为实例：琥珀酸盐、所述酸的二钠盐、二钾盐或酯例如甘油单酯。
甘草酸二钾的化学结构
在优选的实施方案中，甘草次酸衍生物是甘草酸二钾，按相对于组合物的总重量的重量表示，在介于0.1％和1％之间，优选介于0.15和0.3％之间，更优选0.25％的浓度下使用。
组合物用于局部施用。优选地，组合物是水性凝胶或含水醇性凝胶的形式。
在具体实施方案中，根据本发明的组合物是清洗凝胶的形式。
可将凝胶定义为含有胶凝剂以提供用以稳定固体或胶体分散体的粘度的半固体剂型。凝胶可含有悬浮颗粒。
凝胶不含超过5％w/w的亲油相或其它不互溶的相。
凝胶提供用于清洁身体的皮肤表面(且优选面部皮肤)的合适的形式。
本发明的亲水相优选是水性的。
相对于组合物的总重量，水相的存在量可介于10和99重量％之间，优选介于50和95重量％之间并优选包含水。该水可以是纯化水，或花露水例如矢车菊水，或天然泉水或矿物质水，例如选自来自Vittel的水、来自维希盆地(Vichy basin)的水、来自Uriage的水、来自La Roche Posay的水、Avene水或来自Aix les Bains的水。
从而，本发明是局部清洗组合物，其包含：
a.过氧化苯甲酰(BPO)
b.至少一种与BPO相容的温和的表面活性剂，其中所述表面活性剂选自阴离子表面活性剂和/或非离子表面活性剂
c.葡糖酸锌
d.甘草酸二钾。
根据本发明的组合物还可包含至少一种胶凝剂或悬浮剂。
术语“胶凝剂”或“悬浮剂”意欲表示能够维持BPO在悬浮液中的试剂，即使在pH的变化(归因于BPO降解之后的苯甲酸的释放)的影响下也如此。根据本发明的胶凝剂或‘悬浮剂’还赋予制剂合意的物理和化学稳定性特性(例如在介于4和40℃之间的温度下随时间推移没有观察到粘度降低及在介于4和40℃之间的温度下随时间推移没有观察到活性剂的化学降解)。
作为可以是根据本发明的组合物的一部分的“胶凝剂”或“悬浮剂”的非限制性的实例，单独或作为混合物，可提到微晶纤维素和羧甲基纤维素钠混合物(例如由FMCBiopolymer公司销售的Avicel CL-611或RC-S91)；由Noveon公司以名称Ultrez 20TM、Carbopol1382TM销售的“对电解质不敏感的”卡波姆、以名称Pemulen TR1、Pemulen TR2或Carbopol ETD2020TM销售的丙烯酸酯/C10-30烷基交联聚合物；多糖，其非限制性的实例包括黄原胶例如由Kelco公司销售的Xantural 180TM、或结冷胶例如Kelcogel High acyl或low acyl例如Kelcogel F、或还有果胶例如由KELCO销售的Genu pHresh；硅酸铝镁家族，例如由Vanderbilt Minerals LLC公司销售的Veegum KTM或Veegum Ultra、硅酸镁钠、氟硅酸镁钠、硅酸钠镁和由Rockwood公司以商品名Laponite销售的焦磷酸四钠；瓜尔胶，例如来自Rhodia的加尔胶(jaguar)产品；壳聚糖；纤维素及其衍生物，例如羟丙基甲基纤维素(特别是由Dow Chemical公司以名称Methocel E4premiumTM销售的产品)或羟乙基纤维素(特别是由Aqualon公司以名称Natrosol HHX 250TM销售的产品)或羧甲基纤维素钠例如来自Ashland的Blanose；卡拉胶家族特别在以下四个亚家族中的那些：k、λ、β、ω例如由IMCD公司销售的或粘土矿物家族，更精确地，蒙脱石组，例如双八面体蒙脱石(例如膨润土)；与疏水链缔合(associated)的丙烯酸类聚合物家族，例如以名称Aculyn 44TM销售的PEG-150/癸基/SMDI共聚物(缩聚物，其包含至少作为元素的含150或180mol环氧乙烷的聚乙二醇、癸醇和亚甲基双(4-环己基异氰酸酯)(SMDI)，在丙二醇[39％]和水[26％]的混合物中占35重量％)、由Rhom&Haas以名称ACULYN 88销售的丙烯酸酯/硬酯醇聚醚-20(steareth-20)甲基丙烯酸酯交联聚合物、以商品名ACULYN 22销售的丙烯酸酯/硬酯醇聚醚-20甲基丙烯酸酯共聚物、由Noveon-Lubrizol以名称Aqua SF1销售的丙烯酸酯共聚物、聚丙烯酸酯-1交联聚合物(Noveon的Aqua CC)、丙烯酸酯交联聚合物4(Noveon的Aqua SF2)或以商品名Novethix L-10销售的丙烯酸酯/山萮醇聚醚-25(beheneth-25)甲基丙烯酸酯共聚物、由Seppic公司以名称SEPIPLUS 400销售的聚丙烯酸酯-13和聚异丁烯和聚山梨酯20；和聚丙烯酰胺家族的胶凝剂，例如由Seppic公司以名称Simulgel600PHATM销售的丙烯酰二甲基牛磺酸钠共聚物/异十六烷/聚山梨酯80混合物、或聚丙烯酰胺/异链烷烃C13-14/月桂醇聚醚-7混合物诸如，例如由Seppic公司以名称Sepigel 305TM销售的那种，由Seppic公司以名称SEPINOV EMT 10销售的丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物；和改性淀粉家族，例如以名称Structure SolanaceTM销售的改性马铃薯淀粉，或其混合物，
胶凝剂也可以是中和的聚合磺酸，例如由Clariant公司以商品名ARISTOFLEX TAC销售的丙烯酰二甲基牛磺酸铵/丙烯酸羧乙酯交联聚合物。
优选的胶凝剂来源于单独使用或作为混合物使用的丙烯酸类聚合物家族或“抗电解质的”卡波姆，例如Carbopol 1382TM或Carbopol ETD2020；多糖家族，例如黄原胶或果胶；纤维素衍生物，例如羟丙基甲基纤维素或羟乙基纤维素；和膨润土，例如来自AmericainColloid公司的Polargel HV或来自Rockwood的Optigel CK；和硅酸铝镁，例如来自Vanderbilt Minerals LLC的Veegum K和Veegum ultra；和中和的聚合磺酸聚合物，例如丙烯酰二甲基牛磺酸铵/丙烯酸羧乙酯交联聚合物。更优选地，在根据本发明的凝胶组合物中，胶凝剂是硅酸铝镁，例如Veegum K和Veegum ultra和/或黄原胶。
如上所述的胶凝剂可在从0.001％至15％范围的优选浓度(更优选介于0.15％和7％之间)下使用。
根据本发明的组合物还可特别包含至少一种润湿剂。润湿能力是液体在表面上扩展的倾向。
优选地，它们是具有7至18的HLB(亲水/亲油平衡)的润湿剂，或聚氧乙烯化和/或聚氧丙烯化共聚物类型的非离子润湿剂或例如诸如多库酯钠(sodium docusate)之类的阴离子润湿剂。作为润湿剂的非限制性实例，可提到泊洛沙姆，更尤其由Croda(前身Uniqema)销售的称为Synperonic PE/L44和/或Synperonic PE/L62的产品；二醇，例如称为丙二醇、一缩二丙二醇、月桂二醇、二壬酸丙二醇酯、乙氧基二甘醇的那些。它们应当是液体，以利于无需加热就易于并入组合物中。
在润湿剂(其作用是减小表面张力并允许液体在固体颗粒表面上的更大扩展)中，优选使用以下化合物(不限于该列表)：例如泊洛沙姆和/或二醇家族的那些，且更尤其是Synperonic PE/L44和/或Synperonic PE/L62；和/或化合物例如丙二醇、一缩二丙二醇、二壬酸丙二醇酯、月桂二醇(lauroglycol)、乙氧基二甘醇。
作为优选的润湿剂，可提到单独使用或混合使用的丙二醇或Synperonic PE/L44(Poloxamer 124TM)。
以相对于总的组合物重量的重量计，用在根据本发明的组合物中的润湿剂的浓度介于0.001％和20％之间，优选介于0.1％和10％之间及更优选介于1至7％之间。
术语“局部施用”意欲表示向皮肤或粘膜施用。
根据本发明的组合物可进一步包含至少一种以下作为实例提到的添加剂，其在组合物中单独使用或组合使用：
-抗氧化剂，例如维生素E及其衍生物，例如来自Roche的DLα-生育酚或生育酚醋酸酯；维生素C及其衍生物，如抗坏血酸棕榈酸酯(Roche)；由Clariant以名称Nipanox BHT销售的丁基化羟基甲苯、焦亚硫酸钠、维生素，例如维生素PP或烟酰胺
-舒缓剂和/或抗刺激剂，例如由Bertek Pharmaceuticals以商品名Polyolprepolymer-2销售的PPG-12/SMDI共聚物或尿囊素或其衍生物、或透明质酸、聚季铵盐-51(例如由Rossow销售的lipidure PMB)、D-泛酰醇、芦荟(aloe vera)。
-卵磷脂
-胆固醇
-防腐剂：例如苯扎氯铵、溴硝醇(bronopol)、氯己定、氯甲酚及其衍生物、乙醇、苯氧乙醇、山梨酸钾、苯甲酸钠、重氮烷基脲(diazolidinylurea)、苄醇、尼泊金酯或其混合物，由Clariant以名称Nipagin M销售的尼泊金甲酯、由Clariant以名称Nipasol销售的尼泊金丙酯或由Clariant以商品名Nipastat销售的它们的混合物。
-酸或碱，例如柠檬酸、乳酸、茴香酸、柠檬酸钠、三乙醇胺、氨甲基丙醇、氢氧化钠、二异丙醇胺，
-螯合剂，例如EDTA及其盐，例如EDTA二钠。
-湿润剂，例如丙二醇、甘油、戊二醇、1,2-己二醇或辛二醇(caprylyl glycol)、1,3-丙二醇。泡沫促进剂，其选自例如在组合物中单独使用或组合使用的聚乙二醇(例如PEG-75)、或单辛酸甘油酯(来自Sasol的Imwitor 308)、失水山梨醇倍半辛酸酯(来自Evonik的Antil soft SC)。
-为泡沫提供柔滑的成分，其选自PEG-7甘油椰油酸酯、PEG 200氢化甘油棕榈酸酯(来自Evonick的Antil 200)、聚对苯二甲酸丙二醇酯(来自Clariant的Aristoflex PEA)、乳酸C12–13烷基酯(来自Sasol的Cosmacol ELI)，并在组合物中单独使用或组合使用。
-香料增溶剂，例如单独使用或组合使用的PEG-40氢化蓖麻油、PEG-60氢化蓖麻油、聚山梨酯80、聚山梨酯20。
-香料或为组合物提供芳香的成分，例如天然油或精油。
-加脂剂(refatting agents)，例如来自Cognis的Lamesoft PO 65(椰油基葡糖苷和油酸甘油酯)、来自Sasol的softigen 767(PEG-6辛酸/癸酸甘油酯)。
在优选实施方案中，根据本发明的组合物是局部清洗组合物，特征在于其包含：
a.过氧化苯甲酰
b.至少一种阴离子表面活性剂和/或非离子表面活性剂，其选自椰油醇聚醚硫酸酯锌、椰油酰羟乙磺酸钠、月桂酰甲基羟乙磺酸钠、C14-C16α-烯烃磺酸盐和癸基葡糖苷，
c.葡糖酸锌
d.甘草酸二钾
e.至少一种胶凝剂，其选自单独的或作为混合物的聚丙烯酰胺家族、“对电解质不敏感的”卡波姆、多糖、纤维素衍生物、膨润土、硅酸铝镁和中和的聚合磺酸。
根据优选的实施方案，清洗组合物是发泡组合物。
根据另一优选的实施方案，组合物是凝胶的形式。
根据本发明的组合物是稳定的。
更优选地，根据本发明的组合物包含：
a.介于1％w/w和5％w/w之间的过氧化苯甲酰
b.按相对于组合物的总重量的活性材料的重量表示，总浓度介于0.5％w/w和5％w/w之间的至少一种阴离子表面活性和/或非离子表面活性剂，其选自椰油醇聚醚硫酸酯锌、椰油酰羟乙磺酸钠、月桂酰甲基羟乙磺酸钠、C14-C16α-烯烃磺酸盐和癸基葡糖苷，
c.介于0.1w/w和1％w/w之间的葡糖酸锌
d.介于0.1w/w和1％w/w之间的甘草酸二钾
e.介于0.15w/w和7％w/w之间的至少一种胶凝剂，其选自单独的或作为混合物的聚丙烯酰胺家族、“对电解质不敏感的”卡波姆、多糖、纤维素衍生物、膨润土、硅酸铝镁和中和的聚合磺酸。
本发明进一步涉及如本文所定义的组合物，其用于改善、预防或抑制如下文所定义的与痤疮相关的皮肤病的用途。
根据优选的实施方案，本发明涉及这样的组合物，其用于预防、抑制或治疗寻常痤疮的用途。
本发明的另一主题是根据本发明的组合物用于治疗和/或预防与痤疮治疗相联系的皮肤病(特别是寻常痤疮、粉刺性痤疮、丘疹脓疱性痤疮、丘疹粉刺性痤疮、结节囊性痤疮、聚合性痤疮、颈项部瘢痕瘤性痤疮、复发性粟粒状痤疮、坏死性痤疮、新生儿痤疮、职业性痤疮、玫瑰痤疮、老年性痤疮、日光性痤疮和药物性痤疮)的用途。优选地，药物组合物的制剂意欲用于预防、抑制或治疗寻常痤疮。
本发明还提供用于改善和/或预防和/或抑制与痤疮治疗相关联的皮肤病症的方法。本发明还提供用于修饰皮肤或其表面外观的治疗方法，其中将在生理学上可接受的介质中包含BPO的组合物施用到皮肤和/或其皮肤附件(integument annexes)上。在优选的实施方案中，所述治疗针对具有致痤疮(acneic)倾向的皮肤或用于抗击皮肤或头发的油腻外观。
在本文通篇中，除非另外具体说明，应理解，当给出浓度范围时，其包括所述范围的上限和下限。类似地，除非另外指出，组合物的各种组分的比例按所述组合物的总重量的重量百分比(w/w)表示。
本发明的组合物所解决的一个问题是含有BPO的发泡清洗组合物的稳定性。稳定性包括化学稳定性和物理稳定性。
若在各种储存温度(4℃、室温、30℃和40℃)下随着时间推移，组合物的感官特性、pH、粘度和BPO分散体的均匀性保持在限定的参数(范围)内，则认为组合物是物理稳定的。根据本发明，认为室温是包含在介于15℃和25℃之间的温度。
若在各种储存温度(例如4℃、室温、30℃和40℃)下随着时间推移，活性药物浓度保持在限定的参数(范围)内，则认为组合物是化学稳定的。从而，活性药物以相对于并入制剂中的初始量的可接受的百分比存在于组合物中。
根据本发明，当BPO含量在目标活性药物物质浓度的90至110％之内时，认为组合物是化学稳定的。
现借助于以下实施例来阐释本发明，这些实施例不能限制本发明的范围。
以下实施例描述了根据本发明的各种制剂。已通过以下方式分析稳定性：
-测量在各种温度下随着时间推移的剩余BPO，以便确定BPO的化学稳定性。使用高压液相色谱(HPLC)在235nm处紫外(UV)检测进行分析。各实施例(混合物或制剂)中，在各取样间隔处的BPO的浓度表达为初始量的百分比。
-物理分析组合物，以观察BPO悬浮液并评估是否有任何沉淀或附聚。此外，作为物理分析的一部分进行pH和粘度测量及感官评价。
作为一般性观察，根据本发明(实施例1除外)和通过以下实施例证明的所有组合物证明了可接受的物理稳定性，BPO悬浮液没有改性。
现借助于以下实施例来阐释本发明，这些实施例不能限制本发明的范围。
实施例1：证明BPO和传统的两性表面活性剂的化学不稳定性的对比稳定性试验。带有紫外检测的高压液相色谱(HPLC-UV)是用来对样品中的BPO进行定量的方法。
-含有纯化水、BPO和5％椰油酰两性基乙酸钠(两性表面活性剂，由Evonik以产品名AM C销售或来自Stepan的1C)的组合物。
| 组成 | ％w/w |
| 纯化水 | 92.5 |
| BPO | 2.5 |
| 椰油酰两性基乙酸钠 | 5 |
在40℃下，BPO在纯化水和5％椰油酰两性基乙酸钠中1个月之后的化学稳定性
| 取样间隔 | ％BPO(相对于初始值) |
| T0(初始) | 100 |
| T1M(40℃) | <0.1 |
结果显示，1个月之后(T1M)在溶液中未回收到BPO，因而证明在制备期间中加入到组合物中并在初始间隔(T0)测定的所有BPO都降解了。
-含有纯化水、BPO和5％椰油酰两性基二乙酸二钠(两性表面活性剂，由Evonik以产品名AM 2C NM销售)的组合物。
在40℃下，BPO在纯化水和5％椰油酰两性基二乙酸二钠中1个月之后的化学稳定性
| 取样间隔 | ％BPO(相对于初始值) |
| T0(初始) | 100 |
| T1M(40℃) | <0.1 |
结果显示，1个月之后在溶液中未回收到BPO，因而证明在制备期间加入到组合物中并在初始间隔(T0)测定的所有BPO都降解了。
实施例2：BPO与温和的阴离子表面活性剂和非离子表面活性剂的化学稳定性。
-含有纯化水、BPO和5％的来自非离子表面活性剂组的糖酯(蔗糖月桂酸酯)的组合物。
| 组成 | ％w/w |
| 纯化水 | 92.5 |
| BPO | 2.5 |
| 蔗糖月桂酸酯 | 5 |
BPO在纯化水和5％糖酯(蔗糖月桂酸酯)中于40℃下储存2个月之后(T2M)的化学稳定性。
| 取样间隔 | ％BPO(相对于初始值) |
| T0(初始) | 100 |
| T1M(40℃) | 100.0 |
| T2M(40℃) | 99.6 |
结果显示，BPO在纯化水和5％蔗糖月桂酸酯中于40℃下储存2个月之后是稳定的(测定值介于目标的90-110％之间)。
-含有纯化水、BPO和5％癸基葡糖苷(非离子表面活性剂)的组合物。
| 组成 | ％w/w |
| 纯化水 | 92.5 |
| BPO | 2.5 |
| 癸基葡糖苷 | 5 |
BPO在纯化水和5％癸基葡糖苷中于40℃下储存2个月之后的化学稳定性。
| 取样间隔 | ％BPO(相对于初始值) |
| T0(初始) | 100 |
| T1M(40℃) | 96.1 |
| T2M(40℃) | 97.4 |
结果显示，BPO在纯化水和5％癸基葡糖苷中于40℃下储存2个月之后是稳定的。
-含有纯化水、BPO和5％椰油醇聚醚硫酸酯锌(温和的阴离子表面活性剂)的组合物
| 组成 | ％w/w |
| 纯化水 | 92.5 |
| BPO | 2.5 |
| 椰油醇聚醚硫酸酯锌 | 5 |
BPO纯化水、BPO和5％椰油醇聚醚硫酸酯锌于40℃下2个月之后的化学稳定性。
| 取样间隔 | ％BPO(相对于初始值) |
| T0(初始) | 100 |
| T1M(40℃) | 94.7 |
| T2M(40℃) | 97.1 |
结果显示，在40℃下，BPO在该溶液中2个月之后是稳定的。
-含有纯化水，BPO和5％椰油酰羟乙磺酸钠(温和的阴离子表面活性剂)的组合物
| 组成 | ％w/w |
| 纯化水 | 92.5 |
| BPO | 2.5 |
| 椰油酰羟乙磺酸钠 | 5 |
BPO在水、BPO和5％椰油酰羟乙磺酸钠中于40℃下储存2个月之后的化学稳定性。
| 取样间隔 | ％BPO(相对于初始值) |
| T0(初始) | 100 |
| T1M(40℃) | 100.8 |
| T2M(40℃) | 101.3 |
结果显示，BPO在水和5％椰油酰羟乙磺酸钠的溶液中于40℃下储存2个月之后是稳定的。
-含有纯化水，BPO和5％甲基椰油酰牛磺酸钠(温和的阴离子表面活性剂)的组合物。
| 组成 | ％w/w |
| 纯化水 | 92.5 |
| BPO | 2.5 |
| 甲基椰油酰牛磺酸钠 | 5 |
| 取样间隔 | ％BPO(相对于初始值) |
| T0(初始) | 100 |
| T1M(40℃) | 90.1 |
结果显示，BPO在水和5％甲基椰油酰牛磺酸钠的溶液中于40℃下储存1个月之后是稳定的。
对于实施例3至21，制备过程如下：
步骤1：在主烧杯中，称取所需量的纯化水并在分散硅酸铝镁之前将其加热至75℃。
步骤2：冷却至60℃并在混合的同时加入黄原胶。
步骤3：维持在60℃并继续混合直至胶凝剂被水合，随后加入EDTA和发泡表面活性剂。混合直至均匀。
步骤4：冷却至50℃并在混合的同时并入PEG-75(适当时)和甘草酸二钾。混合直至均匀。
步骤5：冷却至40℃并引入葡糖酸锌，并用柠檬酸调节pH。混合直至均匀。
步骤6：在第二个烧杯中，高剪切并维持在低温下(用冰浴)下，使用泊洛沙姆和丙二醇制备BPO的预分散体。
步骤7：混合的同时在主烧杯中加入BPO的预分散体。继续冷却。
步骤8：混合的同时向制剂中加入其它所需的添加剂(如香料)。冷却至30℃并停止混合。
以下描述的所有实施例在RT(室温)、30℃和40℃下3个月之后是物理稳定的。
实施例3：
| 组成 | ％ |
| 纯化水 | QSAD100 |
| 丙烯酸酯/烷基丙烯酸酯交联聚合物 | 1.5 |
| 甘草酸二钾 | 0.25 |
| 葡糖酸锌 | 0.2 |
| 椰油醇聚醚硫酸酯锌(25％水溶液) | 19.5 |
| 椰油基葡糖苷和油酸甘油酯 | 2 |
| 泊洛沙姆124 | 0.2 |
| 丙二醇 | 4 |
| BPO | 2.6 |
BPO在实施例3的组合物中于RT和30℃下储存3个月之后的化学稳定性：
(**)–测定值＝T0的百分比
数据显示，如实施例3中所述的制剂中，BPO在RT和30℃下化学稳定3个月。
实施例4：
BPO在实施例4的组合物中于RT下储存3个月之后以及于40℃下储存1个月之后的化学稳定性。
(**)–测定值＝T0的百分比
数据显示，在如实施例4中所述的制剂中，BPO在RT下化学稳定3个月，且在40℃下化学稳定1个月。
实施例5：
| 组成 | ％w/w |
| 纯化水 | QSAD100 |
| 硅酸铝镁 | 5 |
| 黄原胶 | 0.5 |
| 甲基椰油酰牛磺酸钠(纯度30％) | 8 |
| PEG-75 | 2 |
| 甘草酸二钾 | 0.25 |
| 葡糖酸锌 | 0.2 |
| EDTA二钠 | 0.1 |
| 苯氧乙醇 | 0.5 |
| 泊洛沙姆124 | 0.2 |
| 丙二醇 | 4 |
| BPO | 2.6 |
实施例6：
BPO在实施例6的组合物中于RT、30℃和40℃下储存3个月之后的化学稳定性：
(**)–测定值＝T0的百分比。
数据显示，在如实施例6中所述的制剂中，BPO在RT、30℃和40℃下化学稳定3个月。
实施例7：
| 组成 | ％w/w |
| 纯化水 | QSAD100 |
| 硅酸铝镁 | 5 |
| 黄原胶 | 0.5 |
| 月桂酰甲基羟乙磺酸钠(纯度85％) | 2.5 |
| PEG-75 | 2 |
| 甘草酸二钾 | 0.25 |
| 葡糖酸锌 | 0.2 |
| EDTA二钠 | 0.1 |
| 苯氧乙醇 | 0.5 |
| BPO | 2.6 |
| 泊洛沙姆124 | 0.2 |
| 丙二醇 | 4 |
| 柠檬酸 | 0.15 |
BPO在实施例7的组合物中于RT和30℃下储存3个月之后以及于40℃下储存2个月之后的化学稳定性：
(**)–测定值＝T0的百分比。
数据显示，在如实施例7中所述的制剂中，BPO在RT和30℃下化学稳定3个月，且在40℃下化学稳定2个月。
实施例8：
实施例9：
BPO在实施例9的组合物中于RT和40℃下储存2个月之后的化学稳定性：
(**)–测定值＝T0的百分比。
数据显示，在如实施例9中所述的制剂中，BPO在RT和40℃下化学稳定2个月。
实施例10：
实施例11：
实施例12：
| 组成 | ％w/w |
| 纯化水 | QSAD100 |
| 硅酸铝镁 | 5.5 |
| 果胶 | 1 |
| C14-C16烯烃磺酸钠 | 1 |
| PEG-75 | 2 |
| 甘草酸二钾 | 0.25 |
| 葡糖酸锌 | 0.2 |
| EDTA二钠 | 0.1 |
| BPO | 2.99 |
| 泊洛沙姆124 | 0.2 |
| 丙二醇 | 4 |
| 柠檬酸 | 0.15 |
| 苯氧乙醇 | 0.80 |
BPO在实施例12的组合物中于RT和30℃下储存3个月之后以及于40℃下储存1个月之后的化学稳定性：
(**)–测定值＝T0的百分比。
数据显示，在如实施例12中所述的制剂中，BPO在RT和30℃下化学稳定3个月，且在40℃下化学稳定1个月。
实施例13：
实施例14：
| 组成 | ％w/w |
| 纯化水 | QSAD100 |
| 硅酸铝镁 | 5 |
| 黄原胶 | 0.5 |
| 癸基葡糖苷(55％水溶液) | 6 |
| PEG-75 | 2 |
| 甘草酸二钾 | 0.25 |
| 葡糖酸锌 | 0.2 |
| EDTA二钠 | 0.1 |
| 苯氧乙醇 | 0.8 |
| BPO | 2.6 |
| 泊洛沙姆124 | 0.2 |
| 丙二醇 | 2 |
| 柠檬酸 | 0.15 |
BPO在实施例14的组合物中于RT和40℃下储存3个月之后的化学稳定性：
(**)–测定值＝T0的百分比。
数据显示，在如实施例14中所述的制剂中，BPO在RT和40℃下化学稳定3个月。
实施例15：
实施例16：
BPO在实施例16的组合物中于RT和30℃下储存3个月之后和于40℃下储存1个月之后的化学稳定性：
(**)–测定值＝T0的百分比。
数据显示，在如实施例16中所述的制剂中，BPO在RT和30℃下化学稳定3个月，且在40℃下化学稳定1个月。
实施例17：
实施例18：
实施例19：
| 组成 | ％w/w |
| 纯化水 | QSAD100 |
| 硅酸铝镁 | 5.0 |
| 黄原胶 | 0.5 |
| 椰油酰羟乙磺酸钠(纯度85％) | 2.5 |
| PEG-75 | 2 |
| 甘草酸二钾 | 0.55 |
| 葡糖酸锌 | 0.80 |
| EDTA二钠 | 0.1 |
| 苯氧乙醇 | 0.8 |
| 泊洛沙姆124 | 0.2 |
| 丙二醇 | 4 |
| BPO | 2.6 |
| 柠檬酸 | 0.15 |
实施例20：
| 组成 | ％w/w |
| 纯化水 | QSAD100 |
| 硅酸铝镁 | 5 |
| 黄原胶 | 0.5 |
| C14-C16烯烃磺酸钠 | 2 |
| PEG-75 | 2 |
| 甘草酸二钾 | 0.25 |
| 葡糖酸锌 | 0.2 |
| EDTA二钠 | 0.1 |
| 苯氧乙醇 | 0.8 |
| 泊洛沙姆124 | 0.2 |
| 丙二醇 | 2 |
| BPO | 5 |
| 柠檬酸 | 0.15 |
实施例21：
实施例22
| 组成 | ％w/w |
| 纯化水 | QSAD100 |
| 膨润土 | 5.2 |
| 黄原胶 | 0.6 |
| C14-C16烯烃磺酸钠 | 2 |
| PEG-75 | 2 |
| 甘草酸二钾 | 0.25 |
| 葡糖酸锌 | 0.2 |
| EDTA二钠 | 0.1 |
| 苯氧乙醇 | 0.8 |
| 泊洛沙姆124 | 0.2 |
| 丙二醇 | 2 |
| BPO | 2.6 |
| 柠檬酸 | 0.15 |
Claims (17)
1.局部清洗组合物，特征在于其包含：
a.按相对于所述组合物的总重量的活性成分的重量表示，介于1％w/w和3.5％w/w之间的过氧化苯甲酰，
b.按相对于所述组合物的总重量的活性材料的重量表示，介于0.5％w/w和5％w/w之间的至少一种阴离子和/或非离子表面活性剂，其选自椰油醇聚醚硫酸酯锌、椰油酰羟乙磺酸钠、月桂酰甲基羟乙磺酸钠和癸基葡糖苷，
c.介于0.1％w/w和1％w/w之间的葡糖酸锌
d.介于0.1％w/w和1％w/w之间的甘草酸二钾
e.介于0.15％w/w和7％w/w之间的至少一种胶凝剂，其选自单独的或作为混合物的聚丙烯酰胺家族、“对电解质不敏感的”卡波姆、多糖、纤维素衍生物、膨润土、硅酸铝镁和中和的聚合磺酸。
2.根据权利要求1所述的组合物，其中其是发泡组合物。
3.根据权利要求1所述的组合物，其中其呈凝胶形式。
4.根据权利要求1－3中的任一项所述的组合物，其中所述胶凝剂选自单独的或作为混合物的多糖和硅酸铝镁。
5.根据权利要求4所述的组合物，其中所述胶凝剂选自单独的或作为混合物的黄原胶和硅酸铝镁。
6.根据权利要求1－3和5中的任一项所述的组合物，其中所述组合物进一步包含润湿剂。
7.根据权利要求6所述的组合物，其中所述润湿剂选自泊洛沙姆和/或二醇家族。
8.根据权利要求6所述的组合物，其中所述润湿剂选自单独使用的或混合使用的丙二醇或synperonic PE/L44。
9.根据权利要求6所述的组合物，其中以相对于总的组合物重量的重量计，所述润湿剂的浓度介于1％至7％之间。
10.根据权利要求1－3、5和7－9中的任一项所述的组合物，其中过氧化苯甲酰呈分散形式。
11.根据权利要求1－3、5和7－9中的任一项所述的组合物，其中按相对于所述组合物的总重量的活性成分的重量表示，所述组合物包含介于2.5％和3.5％之间的过氧化苯甲酰。
12.根据权利要求1－3、5和7－9中的任一项所述的组合物，其中按相对于所述组合物的总重量的重量表示，葡糖酸锌的浓度介于0.15％和0.3％之间。
13.根据权利要求1－3、5和7－9中的任一项所述的组合物，其中按相对于所述组合物的总重量的重量表示，甘草酸二钾的存在浓度介于0.15％和0.3％之间。
14.根据权利要求1－13中的任一项所述的组合物在制备用于预防、抑制或治疗寻常痤疮的药物中的用途。
15.根据权利要求1－13中的任一项所述的组合物在制备用于改善、预防或抑制与痤疮治疗相关联的皮肤病症的药物中的用途。
16.根据权利要求1至13中任一项所述的组合物在制备用于治疗或改善痤疮个体皮肤的药物中的用途。
17.根据权利要求1－3、5和7－9中任一项所定义的组合物，其用于预防、抑制或治疗寻常痤疮的用途。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261725958P | 2012-11-13 | 2012-11-13 | |
| US61/725958 | 2012-11-13 | ||
| PCT/EP2013/073737 WO2014076135A1 (en) | 2012-11-13 | 2013-11-13 | Bpo wash gel composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104918598A CN104918598A (zh) | 2015-09-16 |
| CN104918598B true CN104918598B (zh) | 2018-12-04 |
Family
ID=49622807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380070271.8A Active CN104918598B (zh) | 2012-11-13 | 2013-11-13 | Bpo清洗凝胶组合物 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US10610594B2 (zh) |
| EP (1) | EP2919747B1 (zh) |
| CN (1) | CN104918598B (zh) |
| AU (1) | AU2013346890B2 (zh) |
| BR (1) | BR112015010819B1 (zh) |
| CL (1) | CL2015001275A1 (zh) |
| CY (1) | CY1121069T1 (zh) |
| DK (1) | DK2919747T3 (zh) |
| ES (1) | ES2702576T3 (zh) |
| HK (1) | HK1214175A1 (zh) |
| HR (1) | HRP20182062T1 (zh) |
| HU (1) | HUE041489T2 (zh) |
| LT (1) | LT2919747T (zh) |
| MX (1) | MX361371B (zh) |
| PH (1) | PH12015501045B1 (zh) |
| PL (1) | PL2919747T3 (zh) |
| PT (1) | PT2919747T (zh) |
| RS (1) | RS58019B1 (zh) |
| RU (1) | RU2706695C2 (zh) |
| SA (1) | SA515360422B1 (zh) |
| SG (1) | SG11201503675QA (zh) |
| SI (1) | SI2919747T1 (zh) |
| TR (1) | TR201818989T4 (zh) |
| WO (1) | WO2014076135A1 (zh) |
| ZA (1) | ZA201503298B (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013346891B2 (en) * | 2012-11-13 | 2018-02-08 | Galderma Holding SA | BPO wash emulsion composition |
| WO2017068673A1 (ja) * | 2015-10-21 | 2017-04-27 | マルホ株式会社 | 皮膚用の医薬組成物 |
| CN108472282A (zh) * | 2015-11-09 | 2018-08-31 | 葛兰素史克消费保健（美国）控股有限责任公司 | 新的制剂 |
| WO2019205047A1 (en) * | 2018-04-26 | 2019-10-31 | L'oreal | Two-phase composition for topical application |
| EP3811929A1 (en) * | 2019-10-24 | 2021-04-28 | Koninklijke Philips N.V. | Hypochlorite composition and system and method for preparing a hypochlorite composition and use of the same |
| CN112569129A (zh) * | 2019-09-27 | 2021-03-30 | 嘉兴睿肤丽生物科技有限公司 | 一种酸性护肤水凝胶配方及其制备方法 |
| CN112120960B (zh) * | 2020-10-19 | 2022-08-23 | 上海中翊日化有限公司 | 一种果胶面膜及其制备方法 |
| WO2023112664A1 (ja) * | 2021-12-14 | 2023-06-22 | ロート製薬株式会社 | 過酸化ベンゾイルを含有する医薬外用組成物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100221245A1 (en) * | 2009-02-27 | 2010-09-02 | Audrey Kunin | Topical skin care composition |
| WO2012001082A2 (en) * | 2010-06-30 | 2012-01-05 | Galderma S.A. | Moisturizing composition with spf 30 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3141821A (en) | 1959-03-17 | 1964-07-21 | Lehn & Fink Products Corp | Synergistic combination of alkyl sulfonates, alkylaryl sulfonates and topical antibacterial agents for local antisepsis |
| US3535422A (en) | 1968-03-11 | 1970-10-20 | Stiefel Laboratories | Stable benzoyl peroxide composition |
| US4056611A (en) * | 1973-04-16 | 1977-11-01 | Stiefel Laboratories, Inc. | Therapeutic composition |
| TW203552B (en) * | 1992-02-18 | 1993-04-11 | J Baroody Lloyd | Compositions of clindamycin and benzoyl peroxide for acne treatment |
| US5635469A (en) | 1993-06-10 | 1997-06-03 | The Procter & Gamble Company | Foaming cleansing products |
| DE19719856A1 (de) | 1997-05-12 | 1998-11-19 | Henkel Kgaa | Hautpflegemittel |
| JPH10316555A (ja) | 1997-05-16 | 1998-12-02 | Shionogi & Co Ltd | 高分子化合物を含有するリポソーム外用剤 |
| FR2804321B1 (fr) | 2000-01-28 | 2003-08-15 | Oreal | Utilisation de derives de polyaminoacides pour traiter la seborrhee et les desordres cutanes associes |
| US6403110B1 (en) * | 2000-08-09 | 2002-06-11 | Shaklee Corporation | Topical treatment for oily skin |
| US6774100B2 (en) | 2000-12-06 | 2004-08-10 | Imaginative Research Associates, Inc. | Anhydrous creams, lotions and gels |
| AU2002344231B9 (en) | 2001-05-29 | 2006-01-12 | The Procter & Gamble Company | Skin care kit |
| FR2833841B1 (fr) * | 2001-12-21 | 2005-07-22 | Galderma Res & Dev | Gel comprenant au moins un retinoide et du peroxyde de benzoyle |
| US20040156873A1 (en) | 2003-02-10 | 2004-08-12 | Gupta Shyam K. | Topically Bioavailable Acne and Rosacea Treatment Compositions |
| WO2006041782A1 (en) * | 2004-10-07 | 2006-04-20 | Amcol International Corporation | Conversion of liquid compositions to a powder |
| KR20070099038A (ko) | 2005-01-28 | 2007-10-08 | 바스프 악티엔게젤샤프트 | 화장품 제제를 위한 증점제 형태의 수-중-수 에멀젼중합체의 용도 |
| WO2007062995A2 (en) | 2005-11-30 | 2007-06-07 | Ciba Holding Inc. | Glucan compositions |
| FR2909000B1 (fr) | 2006-11-28 | 2009-02-06 | Galderma Res & Dev S N C Snc | Compositions comprenant du peroxyde de benzoyle, au moins un derive de l'acide naphtoique et au moins un compose de type polymeres de polyurethane ou des derives de celui-ci, et leurs utilisations. |
| EP2005942A1 (en) | 2007-06-11 | 2008-12-24 | GIULIANI S.p.A. | Cosmetic composition for treatment of canities |
| FR2916975B1 (fr) | 2007-06-11 | 2009-09-04 | Galderma Res & Dev | Compositions comprenant au moins un compose retinoide, un compose anti-irritant et du peroxyde de benzoyle, et leurs utilisations |
| US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
| WO2009112905A2 (en) | 2008-03-12 | 2009-09-17 | Koninklijke Philips Electronics N.V. | Real-time digital image processing architecture |
| CN101288640B (zh) | 2008-05-23 | 2010-12-22 | 海南京润珍珠生物技术股份有限公司 | 一种添加珍珠水解液脂质体的祛痘精华液 |
| FR2939039B1 (fr) | 2008-12-01 | 2010-12-31 | Basf Beauty Care Solutions France Sas | Nouvel agent inhibiteur de secretion de sebum |
| WO2010101934A1 (en) | 2009-03-05 | 2010-09-10 | Medicis Pharmaceutical Corporation | Methods and compositions for treating acne |
| GB0912481D0 (en) | 2009-07-17 | 2009-08-26 | Reckitt Benckiser Healthcare I | Skincare compositions |
| KR20110030812A (ko) | 2009-09-18 | 2011-03-24 | 애경산업(주) | 민감성 피부 및 두피용 화장료 조성물 |
| FR2969493B1 (fr) * | 2010-12-23 | 2013-07-05 | Galderma Res & Dev | Mousses dermatologiques obtenues a partir d'un gel ou d'une suspension contenant du bpo |
-
2013
- 2013-11-13 AU AU2013346890A patent/AU2013346890B2/en active Active
- 2013-11-13 PT PT13792892T patent/PT2919747T/pt unknown
- 2013-11-13 MX MX2015006033A patent/MX361371B/es active IP Right Grant
- 2013-11-13 CN CN201380070271.8A patent/CN104918598B/zh active Active
- 2013-11-13 BR BR112015010819A patent/BR112015010819B1/pt active IP Right Grant
- 2013-11-13 WO PCT/EP2013/073737 patent/WO2014076135A1/en active Application Filing
- 2013-11-13 EP EP13792892.5A patent/EP2919747B1/en active Active
- 2013-11-13 PL PL13792892T patent/PL2919747T3/pl unknown
- 2013-11-13 US US14/442,693 patent/US10610594B2/en active Active
- 2013-11-13 DK DK13792892.5T patent/DK2919747T3/en active
- 2013-11-13 ES ES13792892T patent/ES2702576T3/es active Active
- 2013-11-13 RU RU2015122625A patent/RU2706695C2/ru active
- 2013-11-13 TR TR2018/18989T patent/TR201818989T4/tr unknown
- 2013-11-13 HU HUE13792892A patent/HUE041489T2/hu unknown
- 2013-11-13 LT LTEP13792892.5T patent/LT2919747T/lt unknown
- 2013-11-13 RS RS20181463A patent/RS58019B1/sr unknown
- 2013-11-13 SI SI201331299T patent/SI2919747T1/sl unknown
- 2013-11-13 SG SG11201503675QA patent/SG11201503675QA/en unknown
-
2015
- 2015-05-11 PH PH12015501045A patent/PH12015501045B1/en unknown
- 2015-05-12 SA SA515360422A patent/SA515360422B1/ar unknown
- 2015-05-12 CL CL2015001275A patent/CL2015001275A1/es unknown
- 2015-05-12 ZA ZA2015/03298A patent/ZA201503298B/en unknown
-
2016
- 2016-03-02 HK HK16102383.3A patent/HK1214175A1/zh unknown
-
2018
- 2018-12-06 HR HRP20182062TT patent/HRP20182062T1/hr unknown
- 2018-12-19 CY CY181101361T patent/CY1121069T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100221245A1 (en) * | 2009-02-27 | 2010-09-02 | Audrey Kunin | Topical skin care composition |
| WO2012001082A2 (en) * | 2010-06-30 | 2012-01-05 | Galderma S.A. | Moisturizing composition with spf 30 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104918598B (zh) | Bpo清洗凝胶组合物 | |
| CN105007888B (zh) | Bpo洗液乳状组合物 | |
| US10688117B2 (en) | Topical wash composition for use in acne patients | |
| EP2167062B1 (en) | Compositions and uses comprising a retinoid compound, an anti-irritant compound and benzoyl peroxide in acne |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1214175 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |